The Market for Anti-Tuberculosis Drugs in India
This chapter explores how public–private collaborations can be successful in India. Public–private mixes (PPMs) are an important part of the Stop TB campaign globally, but they are especially vital in India. One reason for this is the sheer number of TB patients. India has more people suffering from TB than any other country. Another critical reason is that an overwhelming number of these patients are being treated in the private sector and are often receiving a low quality of care. The chapter follows the pharmaceutical industry's efforts to shape the diagnosis and treatment of TB, homing in on interactions between medical representatives and doctors, and showing how the very materiality of global health interventions (drugs, protocols, policies, recordkeeping) provides the context for the expansion of a private therapeutic market.
Princeton Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
If you think you should have access to this title, please contact your librarian.
To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us.